Trifecta Capital.
India's first venture-debt fund and its best-disclosed: ₹8,700 Cr deployed across 220+ companies, 30+ borrower unicorns, published credit costs (<0.8%, zero capital losses claimed) and >₹700 Cr of equity-kicker gains, plus a growth-equity fund that graduates its best borrowers.
GW GP Score
Trifecta invented the Indian venture-debt category (Fund I, 2015) and runs it the way institutions want it run: publish the credit costs, take equity kickers seriously (>₹700 Cr of gains), and graduate proven borrowers into a dedicated growth-equity vehicle (Leaders Fund: ixigo, Meesho, PharmEasy from the debt book). The disclosure evolution deserves note: 'write-offs <0.6%' (Aug 2024) became 'total credit costs <0.8%' (Feb 2025), a definitional widening, but it remains the only platform-published loss figure in Indian venture debt. IFC's $25M is invested; Fund IV's final close is the open item.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Fund IV final close (₹2,000 Cr; guided end-2025, unconfirmed Jul 2026).
Leaders Fund II: no launch found; the graduation engine needs fresh equity capital.
The definitional drift in the loss claim (<0.6% write-offs → <0.8% 'total credit costs') hints the 2021-22 vintage is costing something.
Computed from current dossier sources; analyst override pending.
The credit desk's benchmark: category creator, only published loss figure, DFI-validated, with a working debt-to-equity graduation engine. G2, Positive.
30+ borrower unicorns, $75bn portfolio value; PharmEasy equity scar
Published credit costs + >₹700 Cr kicker gains + IPO cohort: best evidence on the desk
Category creator, now first into asset-heavy policy sectors
₹1,200-1,500 Cr/yr capacity; Fund IV half-committed at first close
Two founder-MPs own 100%; a decade, no churn found
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
ixigo liquidity clears with credible OFS/block-sale evidence.
Leaders Fund II: no launch found; the graduation engine needs fresh equity capital.
Fund IV final close (₹2,000 Cr; guided end-2025, unconfirmed Jul 2026).
If you allocate to Indian venture debt, this is the reference diligence file: published (if unaudited) credit costs, IFC twice through the wire, and equity kickers that behave like a bonus fund. Push on what moved '<0.6% write-offs' to '<0.8% total credit costs'.
The definitional drift in the loss claim (<0.6% write-offs → <0.8% 'total credit costs') hints the 2021-22 vintage is costing something.
Fund IV final close (₹2,000 Cr; guided end-2025, unconfirmed Jul 2026).
Coverage initiated: inaugural GW GP Score.
PharmEasy equity markdown: undisclosed.: No markdown found — the opposite signal: PharmEasy (API Holdings) reported a positive EBITDA of ₹29.2 Cr for 9M FY26, i.e. an operational turnaround, per Business Standard/Precize coverage. No Trifecta-specific equity valuation disclosed, but the operating trend is now favourable rather than distressed.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
₹5,400 Cr raised · ₹8,700 Cr deployed (incl. recycled) across 3 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| VD Fund IV | raising | ₹2,000 Cr target (incl. greenshoe) | Venture debt | First close Feb 2025 (~half committed); IFC $25M invested Oct 2025; final close guided end-2025: unconfirmed |
| Trifecta Leaders Fund I | 2022Correction onset | ₹1,500 Cr + greenshoe | Growth equity | Debt-to-equity graduation: ixigo, Meesho, PharmEasy, Cars24, Dailyhunt |
| VD Funds I-III | 2015-23First boom | ₹500 / ₹1,025 / ₹1,777 Cr | Venture debt | Fund I was India's first VD fund |
Closest booksProsus Ventures (4 shared) · Elevation Capital (3 shared) · Peak XV Partners (3 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle is still in market or not publicly closed.
Next liquidityixigo · Infra.Market · KreditBee · Battery Smart
2 visible exit events since Jul 2024.
Latest vehicle is still in market or not publicly closed.
9 up / 2 flat / 1 down tracked signals.
No senior departure flagged in key people.
9 up / 2 flat / 1 down
2 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangPharmEasy: names with negative 12-month mark or momentum signals in the reconstructed book.
Repricing began mid-deployment
Unicorn discovery; pricing still forming
2024 IPO cohort
DRHP filed
Pre-IPO at ~$1.5bn
Fund IV-era emerging-sector cohort
Latest cited source appears to be 2025.
2 visible events tracked.
12 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · +0
Peer median 3 · +1
Peer median 74 · +4
Peer median 30 · +37
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
The latest vehicle is raising, unclosed or stale against the current deployment cycle.
Recent · Latest cited source appears to be 2025.
Leaders Fund II: no launch found; the graduation engine needs fresh equity capital.
Track first/final close, LP quality, target-vs-close delta and mandate shift.
Leaders Fund II: no launch found; the graduation engine needs fresh equity capital.
ixigo: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Team data, Performance proxy.
5 total sources · 40% primary
Latest cited source appears to be 2025.
ThePrint/ANI: Fund IV first close (Feb 2025)
Upgrade Team data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
220+ companies financed; exposures below are credit (or Leaders Fund equity where noted).
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Zepto | Consumer & Commerce | 2022 | Venture debt | Unicorn | ▲ | Cross-referenced: 4 equity holders + 2 credit desks on this platform now touch Zepto |
| Meesho | Consumer & Commerce | 2020 | VD → Leaders Fund equity | Public | ▲ | The graduation template |
| ixigo | Consumer & Commerce | 2019 | VD → Leaders Fund equity | Public | ▲ | 2024 IPO cohort |
| BigBasket | Consumer & Commerce | 2019 | ₹100 Cr VD | Acquired | → | Tata-owned; early marquee borrower |
| PharmEasy | Healthcare | 2021 | VD + Leaders equity | Unicorn | ▼ | Stress hit via the equity sleeve, not debt; markdown undisclosed |
| Infra.Market | Logistics & Infra | 2020 | Venture debt | Unicorn | ▲ | DRHP filed |
| Urban Company | Consumer & Commerce | 2020 | Venture debt | Public | ▲ | — |
| KreditBee | Fintech | 2021 | Venture debt | Unicorn | ▲ | Pre-IPO at ~$1.5bn |
| MobiKwik | Fintech | 2021 | Venture debt | Public | → | Listed Dec 2024 at 58% premium |
| Euler Motors | EV & Climate | 2026 | $27.1M debt round (co-led) | Private | ▲ | With BlackSoil, Alteria: the EV/climate Fund IV tilt |
| Battery Smart | EV & Climate | 2024 | Venture debt | Soonicorn | ▲ | Fund IV-era emerging-sector cohort |
| Kissht | Fintech | 2022 | ₹100 Cr NCDs (co-led) | Public | ▲ | Listed May 2026: clean credit outcome |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
₹1,200-1,500 Cr of annual deployment capacity, with Fund IV explicitly tilted to EV, deeptech, climate, AI infrastructure and manufacturing (Hygenco, Euler, Battery Smart): venture debt following industrial policy into asset-heavy sectors, exactly where equity funds fear duration.
100+ borrowers planned at ₹25-30 Cr average
Realisation · are LPs getting paid?
Credit realisation here is published, not inferred: <0.8% total credit costs with zero claimed capital losses across four funds, and >₹700 Cr of realised equity-kicker gains. Self-reported and unaudited, but it is the only such number in the Indian market, and IFC underwrote it twice.
Borrower listed: NCDs from the Jan 2022 round long since serviced; Endiya's equity dossier covers the other side.
2024 IPO cohort with ixigo and BlackBuck: listed at 58% premium.
Definitional drift from '<0.6% write-offs' (Aug 2024) noted: still the market's only published figure
The warrant book pays like a small equity fund
Oct 2025: institutional diligence passed
Guided end-2025; unconfirmed as of Jul 2026
The best-disclosed credit platform in Indian venture: published loss claims, IVCA performance awards, DFI anchors, and a growth-equity sleeve monetising the information edge the debt book generates. GW read: the credit-desk benchmark the others get graded against. E.
What they're doing
Dual engine: venture debt generates borrower information; Leaders Fund converts the best of it into growth equity (ixigo, Meesho, PharmEasy graduations).
Publish the credit costs: disclosure as LP acquisition strategy, validated by IFC twice.
Fund IV tilt into asset-heavy policy sectors: EV, climate, AI infra, manufacturing.
Recyclable corpora stretch effective deployment ~1.6x of raised capital.
What can break
The definitional drift in the loss claim (<0.6% write-offs → <0.8% 'total credit costs') hints the 2021-22 vintage is costing something.
PharmEasy shows the crossover risk: the equity sleeve imports venture beta the debt book was designed to avoid.
Fund IV final close overdue vs guidance while Stride raises globally: the category's LP pool is being contested.
Fund IV final close (₹2,000 Cr; guided end-2025, unconfirmed Jul 2026).
Leaders Fund II: no launch found; the graduation engine needs fresh equity capital.
PharmEasy equity markdown: undisclosed.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
If you allocate to Indian venture debt, this is the reference diligence file: published (if unaudited) credit costs, IFC twice through the wire, and equity kickers that behave like a bonus fund. Push on what moved '<0.6% write-offs' to '<0.8% total credit costs'.
Trifecta's debt book is a scouting network for its equity fund: it sees your portfolio's cash position before you do. Its graduation picks (ixigo, Meesho) were also exit signals worth copying.
Fund IV's EV/climate/AI-infra tilt maps venture debt onto our sector dossiers: where Trifecta lends into capex-heavy themes, the equity down-round is being deferred, not avoided. Read against the Capital Stress Index.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.